DUBLIN--(BUSINESS WIRE)--The "Human Papillomavirus Associated Diseases - Pipeline Insights, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Key Topics Covered:
1. Report Introduction
2. Human Papillomavirus Associated Diseases - Pipeline Insights, 2018 Overview
3. Pipeline Therapeutics
- An Overview of Pipeline Products for Human Papillomavirus Associated Diseases - Pipeline Insights, 2018
4. Comparative Analysis
5. Products in Clinical Stage
- Product Description
- Research and Development
- Product Development Activities
6. Products in Pre-Clinical and Discovery Stage
- Product Description
- Research and Development
- Product Development Activities
7. Therapeutic Assessment
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
8. Inactive Products
- Product Description
- Research and Development
- Product Development Activities
Companies Mentioned
- Lee Pharmaceuticals
- CEL-SCI Corporation
- Aviragen Therapeutics
- Tamir Biotechnology, Inc
- Shanghai Fudan
- Zhangjiang Bio
- Pharmaceutical
- RXi Pharmaceuticals, Corp
- Novan, Inc
- Kite Pharma, Inc.
- Genexine, Inc
- Antiva Biosciences
- Inthera Bioscience AG
- UbiVac, LLC
- Cue Biopharma
